Skip to main content
Contact Us
Subscribe
E-Edition
70°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beigene Ltd ADR
(NQ:
BGNE
)
206.82
+8.23 (+4.14%)
Streaming Delayed Price
Updated: 9:45 AM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
4 Analysts Have This to Say About BeiGene
January 20, 2023
Via
Benzinga
Draganfly To Rally Around 87%? Here Are 10 Other Analyst Forecasts For Friday
January 20, 2023
SVB Leerink raised the price target for BeiGene, Ltd. (NASDAQ: BGNE) from $236 to $300. SVB Leerink analyst Andrew Berens maintained an Outperform rating. BeiGene shares rose 2% to $279.90 in...
Via
Benzinga
FDA Approves BeiGene's Brukinsa For Chronic Lymphocytic Leukemia
January 20, 2023
Via
Benzinga
These Were The Five Best And Worst Performing Large-Cap Stocks In Q4 2022
January 06, 2023
The year 2022 proved to be the worst calendar year for the S&P 500 since 2008. The benchmark index dropped more than 5% in December and almost 20% for the full year. Let’s take a look at the five best...
Via
Talk Markets
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
Biopharma stocks were not immune to the broader market downturn seen for much of 2022.
Via
Benzinga
Zymeworks Cancer Candidate Shows Objective Response Of 41% In Bile Duct Cancer
December 19, 2022
Via
Benzinga
BeiGene Earnings Perspective: Return On Capital Employed
December 12, 2022
Via
Benzinga
What 5 Analyst Ratings Have To Say About BeiGene
December 12, 2022
Via
Benzinga
Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific
December 17, 2022
Boston Scientific will pay $523 million for a 65% stake in Acotec Scientific, a Beijing medical device company. Boston Scientific said the acquisition will build up its presence in China, and it will...
Via
Talk Markets
PayPal To Rally Around 47%? Here Are 10 Other Price Target Changes For Monday
December 12, 2022
Via
Benzinga
BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating
December 08, 2022
On Thursday, China-based BeiGene stock cleared that desired 80-plus benchmark, with a jump to 82 from 77 a day earlier.
Via
Investor's Business Daily
Will Investors Notice Exciting Sign On BeiGene's Chart?
December 06, 2022
Via
Benzinga
Why Shares of BeiGene Were Up Wednesday
December 01, 2022
The Chinese pharmaceutical stock is experiencing a comeback.
Via
The Motley Fool
Workday, XPeng, Titan Machinery And Some Other Big Stocks Moving Higher On Wednesday
November 30, 2022
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
What 4 Analyst Ratings Have To Say About BeiGene
November 10, 2022
Analysts have provided the following ratings for BeiGene (NASDAQ:BGNE) within the last quarter:
Via
Benzinga
Why Leslie's Shares Are Trading Lower By Over 9%? Here Are 60 Stocks Moving In Wednesday's Mid-Day Session
November 30, 2022
Gainers Biophytis S.A. (NASDAQ: BPTS) shares jumped 114% to $0.7496. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) rose 74.1% to $0.2115.
Via
Benzinga
Why Horizon Therapeutics Shares Are Trading Higher By Over 30%; Here Are 32 Stocks Moving Premarket
November 30, 2022
Gainers Kalera Public Limited Company (NASDAQ: KAL) shares rose 33.3% to $0.2399 in pre-market trading after jumping 45% on Tuesday. Kalera recently announced restructuring process for German...
Via
Benzinga
Is This Chinese Pharmaceutical Stock Worth the Risk?
November 03, 2022
BeiGene's shares are down this year, but it has two potential blockbusters.
Via
The Motley Fool
European Heath Agency's Committee Backs Approving BeiGene's Brukinsa In Leukemia Setting
October 14, 2022
Via
Benzinga
Dollar Tree, Dycom Industries, Chico's FAS And Other Big Losers From Tuesday
November 23, 2022
U.S. stocks closed higher on Tuesday, with the Dow Jones gaining around 400 points. Here is the list of some big stocks recording losses in the previous session.
Via
Benzinga
Tesla, Amazon, Coupang, Rivian, Beigene: Musk's Share Sale, Antitrust Lawsuit, Earnings Grab Retail Investors' Eyeballs
November 09, 2022
Major Wall Street indices closed nearly 2% lower on Wednesday after the day was marred by uncertainties including the outcome of the mid-term elections and a sell-off in the cryptocurrency...
Via
Benzinga
Jazz Obtains Exclusive Rights To Zymeworks' Cancer Candidate In Almost $2B Biobuck Deal
October 19, 2022
Via
Benzinga
New Drugs Approvals Bring No Relief for Ailing Innovent Bio
October 18, 2022
Key Takeaways: Innovent Bio has brought several drugs to market in recent years, including two announced last week, but is still losing money with no profits in sight The company has overhauled its...
Via
Benzinga
Analyst Ratings for BeiGene
October 13, 2022
Analysts have provided the following ratings for BeiGene (NASDAQ:BGNE) within the last quarter:
Via
Benzinga
UK's NICE Recommends BeiGene's Cancer Drug For Rare Form Of Blood Cancer
September 20, 2022
Via
Benzinga
Week In Review: Jemicare Out-Licenses Prostate Cancer Therapy To Roche For $650 Million
October 15, 2022
Deals, financings, trials and approvals on the China biotech/pharma market.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
October 13, 2022
Upgrades
Via
Benzinga
BeiGene Takes On Johnson & Johnson's Blockbuster Cancer Drug — And Wins
October 12, 2022
A smaller biotech tested its experimental leukemia drug against J&J's approved med.
Via
Investor's Business Daily
BeiGene's Brukinsa Shows Superior Progression-Free Survival Versus JNJ's Treatment
October 12, 2022
Via
Benzinga
BeiGene's Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs Standard Treatment In Solid Tumors
September 12, 2022
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.